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Abstract
Tumor cells exhibit an altered metabolism characterized by elevated aerobic glycolysis and lactate secretion which is
supported by an increase in glucose transport and consumption. We hypothesized that reducing or eliminating the
expression of the most prominently expressed glucose transporter(s) would decrease the amount of glucose available to
breast cancer cells thereby decreasing their metabolic capacity and proliferative potential. Of the 12 GLUT family glucose
transporters expressed in mice, GLUT1 was the most abundantly expressed at the RNA level in the mouse mammary tumors
from MMTV-c-ErbB2 mice and cell lines examined. Reducing GLUT1 expression in mouse mammary tumor cell lines using
shRNA or Cre/Lox technology reduced glucose transport, glucose consumption, lactate secretion and lipid synthesis in vitro
without altering the concentration of ATP, as well as reduced growth on plastic and in soft agar. The growth of tumor cells
with reduced GLUT1 expression was impaired when transplanted into the mammary fat pad of athymic nude mice in vivo.
Overexpression of GLUT1 in a cell line with low levels of endogenous GLUT1 increased glucose transport in vitro and
enhanced growth in nude mice in vivo as compared to the control cells with very low levels of GLUT1. These studies
demonstrate that GLUT1 is the major glucose transporter in mouse mammary carcinoma models overexpressing ErbB2 or
PyVMT and that modulation of the level of GLUT1 has an effect upon the growth of mouse mammary tumor cell lines in
vivo.
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Introduction
The altered metabolism of cancer cells characterized by high
rates of glucose consumption and glycolysis was described by Otto
Warburg eighty years ago [1]. The use of positron emmission
tomography (PET) to detect tumors and/or metastatic lesions
relies upon uptake of a radioactive glucose analog by tumors which
also demonstrates the increased glucose utilization by the majority
of tumors [2]. Tumor hypoxia (due to proliferation outpacing a
blood supply) and subsequent activation of Hypoxia Inducible
Factor (HIF) is certainly responsible for some of the increased
glycolysis and glucose consumption observed in cancer cells since
HIF activates transcription of a number of glycolytic genes as well
as GLUT1 [3,4,5]. However, hypoxia cannot be completely
responsible for the elevated glucose transport and increased
glycolysis observed in tumor cells since these properties are
induced by oncogene-mediated cell transformation in vitro under
normoxic conditions [6,7].
Glucose is transported into cells via two classes of hexose
transporters: the GLUT family and the sodium-dependent glucose
transporter (SGLT) family. The SGLT family of transporters
transport sugars against the concentration gradient utilizing the
sodium-electrochemical gradient and are predominantly expressed
in the small intestine and the kidney [8,9], although recent data
suggests SGLT1 may be expressed in cancer cells that express the
epidermal growth factor receptor (EGFR) [10]. The GLUT family
includes fourteen hexose transporters (twelve in mouse) which are
facilitative transporters that transport sugars along the concentra-
tion gradient [11,12]. GLUT4 is the insulin responsive transporter
and is expressed in adipose tissue and skeletal muscle [13]. The
most widely expressed hexose transporter is GLUT1 which is
thought to maintain basal glucose transport in most types of cells
[11,12]. GLUT1 also appears to be the predominant glucose
transporter in many types of cancer cells [14,15,16,17,18,19],
including breast cancer, although expression of GLUT2, GLUT3,
GLUT5, GLUT6 and GLUT12 have been detected in cancer
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23205cells using immunohistochemistry or RNA analysis [14,16,18,20].
Additionally, the expression of GLUT1 often correlates with the
ability to detect tumors by PET [21,22,23].
We previously described high levels of lactate (indicative of
aerobic glycolysis), low concentrations of glucose (indicative of
high rates of glucose consumption) and elevated expression of
GLUT1 in mammary tumors from MMTV-c-ErbB2 mice and
that these changes were further enhanced in tumors that arose in
the bitransgenic MMTV-c-ErbB2, MMTV-myr-Akt1 mice [24].
We hypothesize that GLUT1 is a critical mediator of cell survival,
proliferation, glucose uptake and aerobic glycolysis in breast
cancer cells in vitro and in mammary tumors in vivo, and tested this
hypothesis using ErbB2 or PyVMT overexpressing mouse
mammary carcinoma cell lines and tumors.
Materials and Methods
Ethics Statement
All mice were maintained in the Center for Comparative
Medicine at the University of Colorado Denver - Anshutz Medical
Campus, an AALAC-approved facility. Additionally, the Univer-
sity of Colorado Denver Institutional Animal Care and Use
Committee specifically approved this study and the protocols used
during this study (Protocol #23103607(11)2E).
Cell Culture
Mouse mammary tumor cell lines (78617, 78622, 78717, 85815
and 85819) generated from tumors arising in MMTV-c-ErbB2
mice were obtained from the laboratory of Ann Thor (University
of Colorado School of Medicine) [25]. 293T and Bosc packaging
cells were obtained from the Tissue Culture Core, University of
Colorado Cancer Center. Met1 cells were provided by Haihua Gu
(University of Colorado School of Medicine). Other cell lines were
from laboratory stocks. All cell lines were cultured in DMEM
containing 10% fetal bovine serum, 40 ng/ml insulin, 16 non-
essential amino acids and 100 units/ml penicillin, 100 mg/ml
streptomycin. Fetal calf serum was obtained from Hyclone (Logan,
UT). All media components were from Invitrogen (Carlsbad, CA)
or Sigma-Aldrich (St. Louis, MO).
Expression Vectors and Virus Preparation
pLKO.1 lentiviral plasmids containing shRNA constructs
targeting mouse GLUT1 or control shRNA were from Open
Biosystems (Huntsville, AL). The human GLUT1 gene was
removed from pSPMM1 [26] (provided by Mike Muekler;
Washington University, St. Louis, MO) as BamH1/BamH1
fragment and subcloned into the pQCXIP retroviral vector
(Clonetech; Mountain View, CA). The GFP-luciferase gene was
removed from pEGFP-LUC2 (provided by Chuan-Yuan Li;
University of Colorado School of Medicine) as a Not1/HindIII
fragment and subcloned into the pLNCX2 retroviral vector. The
pMIG-PyVMT plasmid [27] was provided by Heide Ford,
University of Colorado School of Medicine. Lentivirus was
prepared by cotransfecting 10 cm plates of 293T cells with
10.7 mg pLKO.1 proviral plasmid, 8 mgp D8.9 helper plasmid and
5.3 mg pVSVG envelope plasmid using the calcium phosphate
method. Retrovirus was prepared by cotransfecting 60 mm plates
of Bosc packaging cells with 2 mg retroviral plasmid and 1 mg
pCL-Eco plasmid. Virus containing supernatants were harvested
after 48 hours, filtered through a 0.45 mm filter and target cells
infected in the presence of 8 mg/ml polybrene. Drug-resistant cells
were selected 48 hours after infection with either 2 mg/ml
puromycin or 0.5 mg/ml G418. Adenovirus expressing GFP
(Ad-GFP) or adenovirus expressing Cre recombinase (Ad-Cre)
were provided by Jerome Schaack (University of Colorado School
of Medicine). Adenovirus particle concentrations were determined
spectrophotometrically, with one A260 unit considered equal to
10
12 particles (or 10
10 plaque forming units) as described
previously [28].
Generation of Mice with Floxed GLUT1 Allele
The murine GLUT1 (slc2a1) locus was isolated from a bacterial
artificial chromosome (BAC) clone that was obtained from
Clontech. The source of the DNA was a male CJ7/129SV. A
9.1 kb fragment from EcoR1 (8055) to HindIII (17172) that
encompasses intron 2, exons 3–10 and intron 10 of the GLUT1
locus was subcloned. The 59 loxP site was subcloned into an Nco1
site (11074) in intron 2. An frt-Neo-frt-loxP cassette was subcloned
into an EcoR1 site (14615) located in intron 9. The final targeting
vector was subcloned into the TK1-TK2 C vector containing 2
thymidine kinase cassettes in the tandem with the vector. The
linearized vector was electroporated into isogenic W9.5 embryonic
stem cells at the Embryonic Stem Cell Laboratory in the Section of
Comparative Medicine, Yale University School of Medicine. 276
Neo resistant clones were screened and one recombinant ES cell
clone was obtained and homologous integration was confirmed by
Southern blot and PCR (Figure S2). This ES cell clone was
expanded and injected into the blastocysts of C57BL6 mice.
Chimeric mice were obtained and germline transmission was
confirmed by Southern blotting. Heterozygous offspring harboring
the modified recombinant (loxP-frt-Neo-frt-loxP) GLUT1 allele
were mated with transgenic mice with germline expression of the
FLPe recombinase and offspring were screened for deletion of the
frt flanked Neomycin cassette, but with retention of the 39 loxP
site. Heterozygous offspring for the floxed GLUT1 allele were
then bred to homozygosity. Maps of the targeted allele and the
genotyping scheme are summarized in l Figures S2, S3.
Generation of G1fP and G1fPt cells
Late pregnant or lactating mice with exons 3–8 of the GLUT1
gene‘‘floxed’’ were euthanized and the #4 mammary glands
surgically excised, minced, digested with 1 mg/ml collagenase and
cultured as described [29] before being infected with polyomavirus
middle T antigen (PyVMT) expressing retrovirus (pMIG-PyVMT
[27]) to immortalize and transform the cell line. The resulting cell
lines were passaged over twenty times to establish stably
proliferating cell lines: ‘‘GLUT1
fl/fl PyVMT mammary cells’’ or
‘‘G1fP’’ cells. G1fP cells were infected with Ad-GFP or Ad-Cre at
a multiplicity of infection (MOI) of 100 prior to carrying out
biochemical studies. G1fP cells which had not been exposed to Cre
recombinase were infected with a luciferase expressing retrovirus
and injected into the mammary fat pad of athymic nude mice, as
described below, and the resulting tumors were used to generate
tumor cell lines in the same manner described above, one of which
is called ‘‘G1fPt’’ cells (the added ‘‘t’’ is to denote that the cells
were reisolated from a tumor).
cDNA Synthesis and qPCR Analysis
RNA was isolated from homogenized tumor samples using
Trizol reagent (Invitrogen; Carlsbad, CA) and from cultured cells
using RNeasy Plus Mini kit (Qiagen; Germantown, PA) following
manufacturers’ instructions. 2 mg total RNA was subjected to
single-strand cDNA synthesis using 2 mM random hexamers,
20 mg/ml oligo-dT and MuMLV reverse transcriptase. qPCR was
performed with a dilution of cDNA equivalent of 50 ng RNA and
the following mouse primer/probe sets (Applied Biosystems; Foster
City, CA): GLUT1–GLUT10, GLUT12, GLUT13, SGLT1,
RPL32 and b-actin. The best fit linear equation generated by the
GLUT1 Is Required for Mammary Tumor Growth
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7 to 7.71610
2 copies/ml) was
used to determine the number of copies of GLUT1, GLUT6,
GLUT8 or GLUT9 in the cDNA generated from 50 ng RNA.
Relative transporter expression was normalized to the expression
of b-actin in preliminary experiments or ribosomal protein L32
(RPL32) in later experiments (and RPL32 expression was
unaltered between the groups being compared). % of RPL32
gene expression was calculated using the equation: (2
DCt)(100)
where DCt=[Ct RPL322Ct GLUT]. % b-actin expression was
calculated the similarly.
Immunoblot analysis
Protein was extracted from minced tumor tissue homogenized
using a polytron or from plates of cultured cells and immunoblot
analysis was performed as previously described [24] using the
following antibodies: anti-GLUT1 (Millipore; Billerica, MA or
AbCam; Cambridge, MA); anti-cytokeratin 18, anti-GFP and anti-
b-actin (Santa Cruz Biotechnology; Santa Cruz, CA).
Glucose Consumption, Lactate Secretion and ATP Assays
Cells were cultured in 24 well plates (200,000 cells/well) for
18 hours, and the glucose and lactate in the conditioned media
was quantified using the Glucose Assay Kit (Sigma-Aldrich; St.
Louis, MO) and the Lactate Assay Kit (BioVision; Mountain
View, CA) following manufacturers’ instructions. The difference in
the amount of glucose in each sample compared to the amount of
glucose in media incubated without cells reflected glucose
consumption. Quantities of glucose consumed and lactate secreted
were normalized to the DNA content of each well and
quadruplicate samples were analyzed. The ATP content of cells
was determined using the ATPlite Luminescence Assay (Perkin
Elmer; Walthan, MA) following manufacturer’s instructions.
Proliferation and DNA Quantitation Assay
10,000 cells were added per well of 24 well plates in
quadruplicate and were cultured for 0–4 days. DNA concentra-
tions of the monolayers collected on successive days were
determined using the Hoechst 33258 assay [30] as a means to
determine relative proliferation. The DNA concentration was also
used to normalize glucose consumption, lactate secretion or ATP
concentration data.
3H -2-deoxyglucose Transport Assay
Cells in 24 well plates (200,000 cells/well) were seeded for
18 hours, washed with PBS, incubated for 1 hour in glucose-free
DMEM, and then pulsed with 2 mCi of
3H-2-deoxyglucose
(,60 pmol) (PerkinElmer; Waltham, MA) for 15 minutes. The
monolayers were washed three times with ice cold PBS, lysed with
0.5 ml 1 M NaOH, neutralized with 0.5 ml 1 M HCl, and
quantitated by liquid scintillation counting. DNA concentrations
of non-radioactive control wells were used to normalize radioac-
tivity incorporation and data is presented as CPM per mg DNA.
Lipid Synthesis Assay
500,000 cells in complete media with 1 mg/ml glucose
containing 500 nCi
14C-U-glucose (Perkin Elmer, Walthan, MA)
were incubated overnight. Media was removed and monolayers
were lysed with 100 ml 0.5% Triton-X-100 and transferred to a
microfuge tube. Methanol:chloroform extraction was performed
by sequentially adding 250 ml methanol, 250 ml chloroform,
250 ml chloroform and 250 ml 0.9% NaCl with vortexing between
each step. The lower lipid containing chloroform phase was
transferred to a scintillation vial and the sample was re-extracted
with an additional 500 ml chloroform which was transferred to the
same vial. Chloroform was evaporated under a stream of nitrogen,
the lipid dissolved in 100 ml ethanol and 5 ml scintillation cocktail
and quantitated by liquid scintillation counting. DNA concentra-
tions of non-radioactive control plates were used to normalize
radioactivity incorporation.
Growth in Soft Agar
30,000 cells were resuspended in 10 ml of 0.4% agar containing
16 DMEM/F12 and 10% FBS, and 3 ml were added to three
different agar coated wells of six well plates. Media was changed
twice weekly, and after three weeks the plates were photographed
with a BioRad Gel Doc imaging system (Hercules, CA) and
colonies quantitated using the colony counting tool (Quantity One
Software). One hour prior to harvest the media was supplemented
with 3 mg/ml BrdU. The plates were washed with PBS and plugs
of soft agar were removed, wrapped in lens paper, fixed for 1 hour
in 10% neutral buffered formalin, processed in a tissue processor
and embedded in paraffin.
Tumor cell transplantation
Tumor cell lines expressing GFP-luciferase or luciferase were
resuspended in 50% matrigel (BD biosciences; Bedford, MA), 50%
PBS to a concentration of 0.4 or 0.5 million cells per 20 ml. 20 ml
cells were back-loaded to insulin syringes and injected into
surgically exposed #4 mammary glands of athymic nude mice
(Jackson Laboratories; Bar Harbor, ME) anesthetized with ,2m g
Avertin (Sigma-Aldrich; St. Louis, MO). Tumor growth was
monitored by bioluminescence by intraperitoneal injection of
200 ml sterile 15 mg/ml D-luciferin (Gold Biotechnology; St.
Louis, MO) followed by anesthetization with 2% isoflourane and
imaging with an IVIS 200 Bioimager (Small Animal Imaging
Core, University of Colorado Cancer Center) seven minutes after
D-luciferin administration. Bioluminescence data was evaluated
using Living Image 2.60.1 software. Two hours prior to sacrifice
and tumor harvest, mice were injected with 500 ml 3 mg/ml BrdU
(GE Healthcare; Pittsburgh, PA).
Histological Analyses
Dissected tumors were fixed in 10% neutral buffer formalin and
processed by the Pathology Core Facility of the University of
Colorado Cancer Center. Antigen retrieval was performed by
heating slides in 10 mM citrate pH 6.0 for 20 minutes in a
microwave. Slides were blocked with 10% normal goat serum and
incubated overnight at 4uC with GLUT1 antibody (Global
Peptide; Fort Collins, CO [24]) diluted to 0.1 mg/ml or rabbit
anti-Ki67 antibody (Abcam; Cambridge, MA) diluted 1:75.
Biotinylated goat anti-rabbit secondary antibody and tertiary
Vector ABC or ABC elite (Vector Laboratories, Burlingame, CA)
was followed by DAB color development and hematoxylin
counterstaining. Detection of apoptotic cells was performed
similarly using SignalStain cleaved caspase-3 IHC detection kit
(Cell Signaling Technologies, Beverly, MA) with pre-diluted rabbit
anti-cleaved capsase-3 antibody. Proliferating cells that had
incorporated BrdU were identified using the anti-BrdU kit from
BD Biosciences following manufacturer’s instructions. Light
photomicrographs were captured using an Olympus BX40
microscope equipped with a Spot Insight QE camera and Spot
Advanced software. Proliferation was quantitated by determining
the total number of nuclei and BrdU-positive or Ki67-positive
nuclei in three-four high power fields in four tumor sections of
each group to determine the percent of positively staining nuclei.
Twelve BrdU stained soft agar colonies per group were analyzed
similarly, but only the outer two cell layers of each colony was
GLUT1 Is Required for Mammary Tumor Growth
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of ‘‘hot spots’’ of cleaved caspase 3 staining were converted to
binary pictures using ImageJ software to quantitate the number of
pixels representing cleaved caspase 3 positive staining in four
tumors from each group.
Statistical Analyses
All data are presented as the mean +/2 standard deviation and *
is used to denote statistical significance (p,0.05) between groups as
determined by two tailed T test assuming unequal variance when
comparing two groups, unless otherwise indicated. Significant
differences (p,0.05) between multiple groups were determined by
ANOVA and Bonferroni post-hoc tests (multiple testing-corrected).
Results
GLUT1 is the most abundantly expressed hexose
transporter in MMTV-c-ErbB2 mammary tumors and
numerous mouse mammary carcinoma cell lines
A qPCR screen evaluating the expression of eleven of the twelve
mouse GLUT family members was performed with the following
samples: tumors derived from MMTV-c-ErbB2 mice [24], two
mammary tumor cell lines derived from such tumors (78617 and
85815 [25]), a mammary carcinoma cell line derived from MMTV-
PyVMT mice (Met1 [31]), a BALB/c mouse mammary carcinoma
cell line (4T1 [32]), and immortalized mouse mammary epithelial
cell line (EPH4). This initial screen demonstrated that GLUT1 was
the most abundantly expressed GLUT family member in ErbB2
overexpressing mouse mammary tumors and all five cell lines
examined (Figure 1A). Other GLUT family members which were
expressed included GLUT6, GLUT8 and GLUT9 (Figure 1A,
Figure 2K). We further analyzed the expression of GLUT1,
GLUT6, GLUT8 and GLUT9 in multiple samples of the ErbB2-
overexpressing tumors and cell lines by performing qPCR against a
standard curve for each transporter to determine the number of
copies of each transporter, independent of any reference gene
(Figure 1B). This analysis demonstrated that GLUT1 was the most
highly expressed transporter in all samples and that all samples also
expressed GLUT8, 78617 cells expressed GLUT6 and the ErbB2
tumors expressed GLUT9 (Figure 1B). These samples all lack
expression of GLUT7 (data not shown, Figure 2K), the one GLUT
family member not examined in our initial screen (Figure 1A).
Immunoblot analysis utilizing lysates from a primary MMTV-c-
ErbB2 mouse mammary tumor and five cell lines derived from
tumors taken from these mice (78617, 78622, 78717, 85815 and
85819) using HeLa cells as a control, revealed that all express
GLUT1 protein (Figure 1C). Numerous immunoreactive bands
are present in GLUT1 immunoblot analysis due to glycosylation of
GLUT1 [33] and later experiments show all bands are reduced by
RNAi or Cre recombinase and conversely all bands are present
when GLUT1 is overexpressed. 85815 cells express very low levels
of the GLUT1 protein demonstrating that GLUT1 protein levels
do not necessarily correlate with the amount of RNA detected by
qPCR (Figure 1A–B). Expression of keratin 18 (K18) demonstrates
that the cell lines are of epithelial origin and all lanes are loaded
similarly (Figure 1B).
Figure 1. GLUT1 is the most abundantly expressed GLUT family member in MMTV-c-ErbB2 tumors and a number of mouse
mammary carcinoma cell lines. A. qPCR analysis to determine the expression of GLUT1–GLUT6, GLUT8–GLUT10, GLUT12–GLUT13 (eleven of the
twelve mouse GLUT family transporters) relative to b-actin expression was performed with the cDNA equivalent of 50 ng RNA in six samples:
mammary tumor from a MMTV-c-ErbB2 mouse (ErbB2 tumor), two different cell lines derived from these tumors (78617 and 85815), a cell line derived
from a MMTV-PyVMT mouse mammary tumor (Met1), a cell line derived from a BALB/c mouse mammary tumor (4T1) and immortalized mouse
mammary epithelial cells (EPH4). B. Quantitation of the number of copies of GLUT1, GLUT6, GLUT8 and GLUT9 RNA in the cDNA derived from 50 ng
RNA from triplicate samples of ErbB2 Tumors, 78617 cells and 85815 cells. * indicates p,0.05 for GLUT1 expression versus the other transporters as
determined by Bonferroni post-hoc tests. C. Immunoblot analysis of GLUT1 and keratin 18 (K18) in lysates of an MMTV-c-ErbB2 tumor (tumor), HeLa
cells, and five different MMTV-c-ErbB2 tumor cell lines (78617, 78622, 78717, 85815 and 85819).
doi:10.1371/journal.pone.0023205.g001
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glucose usage, lipid synthesis and proliferation in vitro
We had previously noted increased lactate concentration,
decreased glucose concentration and increased GLUT1 expression
in tumors from MMTV-c-ErbB2 mice compared to mammary
epithelial cells [24] and wanted to test whether manipulation of
GLUT1 expression levels in ErbB2-overexpressing mammary
carcinoma cells could modulate aspects of glucose usage,
bioenergetics and biosynthesis in vitro. The 78617 cell line was
transduced with a retrovirus encoding GFP-luciferase to create
‘‘78617GL’’ cells. These cells were transduced with lentiviruses
expressing shRNA molecules targeting GLUT1 or a non-silencing
control shRNA to generate pools of cells stably expressing each
shRNA. Immunoblot analysis revealed that the GLUT1 shRNA
effectively reduced GLUT1 protein expression as compared to
cells expressing the control shRNA (Figure 2A). 78617GL cells
with undetectable amounts of GLUT1 protein were viable and
survived in culture for numerous passages and demonstrated no
apparent increase in caspase 3 activation (data not shown). There
was also no difference in the expression of numerous Bcl2 family
members, including PUMA (data not shown), which has been
shown to be increased under conditions of low glucose to mediate
p53-dependent cell death [34].
We sought to determine whether these cells with reduced
GLUT1 protein have altered glucose usage. There is a 35%
decrease in the uptake of
3H-2-deoxyglucose (
3H -2-DOG) in
Figure 2. Reduced expression of GLUT1 in 78617GL cells decreases glucose usage, lipid synthesis and proliferation in vitro. A.
Immunoblot analysis evaluating the expression of GLUT1, GFP-Luciferase transgene (GFP) and b-actin in lysates from 78617GL cells expressing control
shRNA (C) or GLUT1 shRNA (G1). B. Uptake of
3H-2-deoxyglucose by 78617GL cells expressing control shRNA (shCTRL) or GLUT1 shRNA (shGLUT1) in
15 minutes presented as CPM per mg DNA. C–D. Glucose consumption (C) and lactate secretion (D). Glucose and lactate concentrations are
normalized to the DNA content of the cultures. E. Proliferation is estimated by deteriming the DNA content of cultures at days 0, 1, 2 and 3 post-
seeding. F–G. 78617GL cells were grown in soft agar for 3 weeks and colonies are pictured in F and the number of colonies per well is quantified in
G. H. Quantification of BrdU positive cells in the outer edge of 12 colonies of each group. I. The concentration of ATP in the two groups of cells
(lacking luciferase expression) was determined and normalized to the DNA content of parallel monolayers. J. Lipid synthesis was measured by
determining the amount of
14C in the non-aqueous chloroform fraction of methanol chloroform extracted cell lysates after 24 hour incubation with
14C-glucose and is normalized to the DNA content of parallel samples. K. qPCR analysis evaluating the expression of the 12 mouse GLUT transporters
and SGLT1 in 78617GL cells expressing control shRNA or GLUT1 shRNA normalized to RPL32 expression.
doi:10.1371/journal.pone.0023205.g002
GLUT1 Is Required for Mammary Tumor Growth
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e2320578617GL cells expressing GLUT1 shRNA compared to the cells
expressing control shRNA (Figure 2B). Similarly, 78617GL cells
expressing control shRNA consume more glucose and secrete
more lactate than 78617GL cells expressing GLUT1 shRNA
(Figure 2C–D). These data demonstrate that reduction of GLUT1
expression leads to a reduction of glucose transport, glucose
consumption and lactate secretion suggestive of reduced glycolysis
and glucose metabolism.
We wanted to determine if decreasing GLUT1 expression would
reduce proliferation since cell division requires energy (ATP) and
carbon for macromolecule biosynthesis, both of which can be
supplied by glucose. 78617GL cells expressing GLUT1 shRNA had
a reduced rate of proliferation as compared to the cells expressing
the control shRNA, which was apparent on days 1, 2, and 3
(Figure 2E). Similarly, 78617 cells expressing GLUT1 shRNA
formed fewer colonies when grown in soft agar (Figure 2F–G,
Figure S1). Colonies from cells expressing control shRNA and
GLUT1 shRNA had similar patterns of cleaved caspase 3 staining:
larger colonies tended to have staining at the core of the colony
while medium and small colonies tended to have very little cleaved
caspase 3 staining (Figure S1), though the colonies from shGLUT1
cells did appear to have more frequent central apoptosis. Nuclear
BrdU incorporation tended to occur at the perimeter of the colonies
(Figure S1) and 78617GL cells expressing control shRNA had a
higher percentage of BrdU positive nuclei at their edge than
colonies derived from cells expressing GLUT1 shRNA (Figure 2H
and Figure S1) suggesting cells with reduced GLUT1 have reduced
proliferation in soft agar. 78617 cells expressing GLUT1 shRNA or
control shRNA (grown on plastic) had identical concentrations of
ATP (Figure 2I) suggesting that impaired glucose usage and
GLUT1 expression does not deplete ATP under the conditions of
this study. However, 78617GL cells expressing GLUT1 shRNA
cultured with radiolabeled glucose convert less of the aqueous label
to the non-aqueous lipid containing fraction than cells expressing
controlshRNA(Figure2J),suggesting reduced lipid synthesisincells
expressing GLUT1 shRNA.
The shRNA mediated reduction of GLUT1 appears to
eliminate detectable GLUT1 protein by immunoblot analysis
(Figure 2A), but 78617GL cells expressing GLUT1 shRNA still
transport and consume glucose (Figure 2B–C), albeit at a lower
rate than the control cells. qPCR analysis reveals that GLUT1 is
still the most highly expressed GLUT family member in cells
expressing GLUT1 shRNA and that no other GLUT family
member or SGLT1 is being upregulated (at the RNA level) in cells
lacking detectable GLUT1 protein (Figure 2K). Thus, glucose
consumption by cells expressing GLUT1 shRNA may still occur
via remaining GLUT1 (or other transporters) or by non-specific
means such as pinocytosis.
Reduced expression of GLUT1 decreases tumor growth in
nude mice
To address the role of GLUT1 in tumor growth in vivo,
78617GL cells expressing control shRNA or GLUT1 shRNA were
transplanted into contralateral #4 mammary glands of five
athymic nude mice and tumor growth was monitored by
bioluminescence on days 2, 4, 6, and 8 post tumor cell transplant
(Figure 3A) which is quantitated and averaged for all five mice
(Figure 3B). In each mouse, the tumor derived from cells
expressing GLUT1 shRNA was smaller than the contralateral
tumor derived from cells expressing control shRNA, and this
difference was most evident on days 6 and/or 8 (Figure 3A and
data not shown), and this is also true of the average across all five
mice (Figure 3B). Four of the five tumors derived from cells
expressing control shRNA outweighed the contralateral tumor
expressing GLUT1 shRNA (with the fifth tumor pair weighing the
same) (data not shown), which corroborates the bioluminescence
data by suggesting decreased growth of cells expressing GLUT1
Figure 3. Reduced expression of GLUT1 in 78617GL cells
decreases tumor growth. A. 0.5 million 78617GL cells expressing
control shRNA (C) or GLUT1 shRNA (G1) were injected into contralateral
#4 mammary fat pads of athymic nude mice. Bioluminescence from the
labeled tumor cells was detected on days 2, 4, 6 and 8 after
implantation. The abdominal region heat map depicting luciferase
activity of a representative mouse is pictured. B. The average
bioluminescence on days 2, 4, 6 and 8 normalized to the day 2
bioluminescence +/2 SEM for five mice is presented with the black
diamonds representing shCTRL tumors and grey squares representing
shGLUT1 tumors. C. Expression of GLUT1 and b-actin in lysates of three
tumor pairs evaluated by immunoblot analysis. D. GLUT1 expression
evaluated by IHC (with hematoxylin counterstain) in two tumor pairs. E.
Representative low power photomicrographs of two pairs of tumor
sections immunostained for cleaved caspase 3. F–G. Representative
high power photomicrographs of a tumor pair immunostained for BrdU
with hematoxylin counterstain (F) which is quantified (G).
doi:10.1371/journal.pone.0023205.g003
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corroborated these results: 78617GL cells expressing GLUT1
shRNA are smaller than control tumors in their initial ten days of
growth (data not shown).
Immunoblot analysis of tumor lysates and immunohistochem-
ical staining of tumor sections reveals that tumors derived from
78617GL cells expressing GLUT1 shRNA maintain low levels of
GLUT1 protein (Figure 3C–D); however this GLUT1 protein
may reflect either endothelial cells or infiltrating immune cells
present in the tumors analyzed. qPCR analysis revealed that there
was no change in the levels of other GLUT family members
between the two tumor types suggesting that the low level of
GLUT1 was not compensated for by an increase in the expression
of these other GLUTs (data not shown), similar to what was
observed with these cell lines in vitro prior to transplantation into
mice (Figure 2K).
Surprisingly, tumors derived from cells expressing control
shRNA and GLUT1 shRNA both revealed very little staining
for cleaved caspase 3 (Figure 3E). Quantification of cleaved
caspase 3 staining revealed no difference in apoptosis between the
two tumor types (data not shown). Quantification of the
percentage of BrdU positive nuclei in 3 high power images from
four tumors of each type revealed that tumors derived from cells
expressing GLUT1 shRNA had a lower rate of proliferation than
the control tumors (Figure 3F–G). This suggests that the
differences in tumor size more likely reflect differences in
proliferation than differences in apoptosis. Since these tumors
were harvested at an early stage when they weighed ,200 mg,
there was no central necrosis observed.
Eliminating GLUT1 expression in G1fP cells decreases
glucose usage, lipid synthesis and proliferation in vitro
Use of RNAi reduced, but did not eliminate GLUT1 expression
in 78617GL cells, so we generated a system in which we could
eliminate GLUT1 expression. Harvested mammary epithelial cells
from GLUT1
fl/fl mice (Figures S2, S3) were transformed in culture
with the polyomavirus middle T antigen, an oncogene that shares
many similarities to ErbB2 and is frequently used in mouse models
of breast cancer [35], to establish a stably proliferating cell line
named ‘‘G1fP’’ (for Glut1 floxed PyVMT. G1fP cells were infected
at an MOI of 100 with adenovirus expressing GFP or Cre
recombinase which resulted in the expression of GFP and the
elimination of detectable GLUT1, respectively (Figure 4A).
Expression of CK18 in these cells demonstrates their epithelial
origin and equal loading (Figure 4A). G1fP cells exposed to Cre
recombinase had a 60% reduction in
3H -2-DOG transport, a
60% reduction in glucose consumption and an approximate 80%
reduction in lactate secretion as compared to cells exposed to GFP
adenovirus (Figure 4B–D). G1fP cells lacking GLUT1 also had a
reduced rate of proliferation (Figure 4E). While there was no
difference in the ATP content of G1fP cells expressing GLUT1 or
lacking GLUT1 expression (Figure 4F), the cells lacking GLUT1
expression had a greater than 60% decrease in the flux of glucose
into lipid (Figure 4G). The expression of the GLUT family of
Figure 4. Eliminating expression of GLUT1 in G1fP cells decreases glucose usage, lipid synthesis and proliferation in vitro. A.
Immunoblot analysis evaluating the expression of GLUT1, GFP, CK18, and b-actin in lysates from GLUT1
fl/fl mammary cells transformed with PyVMT
(G1fP cells) 72 hours after being infected with adenovirus expressing GFP (Ad-GFP) or Cre recombinase (Ad-Cre) at an MOI of 100. B–D. Uptake of
3H-
2-deoxyglucose (B), glucose consumption (C), and lactate secretion (D) by G1fP cells previously infected with Ad-GFP or Ad-Cre as described in
figure 2. E. Proliferation is estimated by determining the DNA content of cultures at days 0, 1, 2 and 3 post-seeding. F. The concentration of ATP in
the two groups of cells was determined and normalized to the DNA content of parallel monolayers. G. Lipid synthesis in G1fP cells was measured as
described in figure 2. H. qPCR analysis evaluating the expression of the 12 mouse GLUT transporters and SGLT1 normalized to RPL32 expression in
G1fP cells that had been infected two weeks prior with Ad-GFP or Ad-Cre.
doi:10.1371/journal.pone.0023205.g004
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23205Figure 5. Elimination of GLUT1 expression in G1fPt cells decreases tumor growth. A. 0.5 million G1fPt cells infected two weeks prior with
adenovirus expressing GFP or Cre recombinase were injected into contralateral #4 mammary fat pads of athymic nude mice. Bioluminescence from
the labeled tumor cells was detected on days 12, 15 and 20 after implantation. The abdominal region heat map depicting luciferase activity of a
representative mouse is pictured. B. The average bioluminescence on days 12, 15 and 20 +/2 SEM for eight mice is presented with green diamonds
representing ‘‘GFP’’ tumors and light blue squares representing ‘‘Cre’’ tumors. C. Expression of GLUT1 and b-actin in lysates of two tumor pairs
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line preferentially expressed GLUT1 with low level expression of
GLUT3, GLUT6, and GLUT8, but removal of GLUT1 by Cre
recombinase did not increase the expression of any of the other
remaining hexose transporters (Figure 4H).
Eliminating expression of GLUT1 decreases tumor
growth in nude mice
To test whether G1fP cells, which were transformed in culture,
are capable of tumor formation, G1fP cells expressing luciferase
exposed to Ad-GFP or Ad-Cre were injected into contralateral #4
mammary glands of three athymic nude mice. In all three mice, the
cells which had been exposed to GFP formed tumors with latencies
ranging from 55–120 days while the mammary glands injected with
cells exposed to Cre recombinase had no palpable tumor at the time
of sacrifice or by later histologic examination (data not shown). A
tumor cell line, ‘‘G1fPt’’ (for G1fP tumor), was generated from the
first tumor arising from injected Ad-GFP infected G1fP cells. G1fPt
cells were expanded in culture and then exposed to Ad-GFP or Ad-
Cre and lysates evaluated by immunoblot analysis as described to
confirm GLUT1 expression and elimination (data not shown).
G1fPt cells exposed to Ad-GFP or Ad-Cre were injected into
contralateral mammary glands of eight athymic nude mice and
tumor development was monitored by bioluminescence on days 12,
15 and 20 post-injection (Figure 5A). The average bioluminescence
from the two tumor types was similar on day 12, but by day 20, the
tumors from the cells exposed to Cre were more than 35% smaller
than the tumors with GLUT1 intact (Figure 5B). Similarly, in six of
the eight harvested tumor pairs, the tumor from cells exposed to
GFP weighed more than the tumor from cells exposed to Cre; and
only one Cre tumor weighed more than the contralateral GFP
tumor (data not shown). Examination of GLUT1 expression in the
tumors by immunoblot analysis and IHC demonstrates that the
tumors from Ad-Cre infected cells maintain reduced GLUT1
expression as compared to the control GFP tumors (Figure 5C–D).
Both tumor types had similar, low levels of cleaved caspase 3
staining (Figure 5E). Tumor sections were stained for Ki67
(Figure 5F), a proliferation marker, and tumors from cells exposed
to Cre recombinase had a 25% lower proliferative index than the
tumors exposed to GFP (Figure 5G). These results corroborate the
data from 78617GL cells: cells with reduced GLUT1 have reduced
proliferation and form tumors more poorly than the control cells.
Overexpression of GLUT1 in 85815GL cells increases
glucose transport without increasing proliferation
85815 cells contain low levels of GLUT1 protein compared to
the other mouse mammary tumor cell lines examined (Figure 1B)
and reduction of GLUT1 in 85815 cells does not reduce
proliferation of these cells in vitro or tumor growth initiated by
these cells in vivo (data not shown). To ask whether increasing the
level of GLUT1 in these cells would enhance proliferation and
tumor growth in vivo, GLUT1 was overexpressed in 85815 cells
expressing GFP-luciferase (85815GL cells).
85815GL cells were infected with a retroviral vector encoding
human GLUT1 cDNA followed by selection in puromycin-
containing media. Immunoblot analysis of lysates from these cells
demonstrates greatly elevated levels of GLUT1 as compared to
cells transduced with an empty vector control (Figure 6A).
Overexpression of GLUT1 increased
3H-2-DOG transport
greater than five-fold as compared to the empty vector control
cells (Figure 6B), demonstrating that the overexpressed GLUT1
was functional. The overexpression of GLUT1 in 85815GL cells
did not increase proliferation and in fact proliferation slowed
slightly by day 3 (Figure 6C).
Overexpression of GLUT1 accelerates tumor formation
To examine whether overexpression of GLUT1 stimulates
tumor growth, 85815GL cells overexpressing GLUT1 or empty
vector were injected into contralateral mammary glands of five
athymic nude mice and tumor growth monitored by biolumines-
cence on days 3, 6, 9, 12 and 14 post tumor cell transplant
(Figure 7A). Each tumor derived from cells overexpressing
evaluated by immunoblot analysis. D. GLUT1 expression evaluated by IHC (with hematoxylin counterstain) in two tumor pairs. E. Representative low
power photomicrographs of two pairs of tumor sections immunostained for cleaved caspase 3. F–G. Representative high power photomicrographs
of a tumor pair immunostained for Ki67 with hematoxylin counterstain (F) which is quantified (G).
doi:10.1371/journal.pone.0023205.g005
Figure 6. Overexpression of GLUT1 in 85815GL cells increases glucose transport without increasing proliferation. A. Expression of
GLUT1, GFP-luciferase and b-actin in lysates of 85815GL cells expressing empty vector (V) or overexpressing GLUT1 (G1). B. Uptake of
3H-2-
deoxyglucose by cells expressing empty vector (Vec) or GLUT1 (GLUT1) in 15 minutes presented as CPM per mg DNA. C. Proliferation is estimated by
determining the DNA content of cultures expressing empty vector or GLUT1 at days 0, 1, 2 and 3.
doi:10.1371/journal.pone.0023205.g006
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14, and the average bioluminescence shows that as a group the
tumors overexpressing GLUT1 were bigger on days 12 and 14
(Figure 7B). Additionally, weights of tumors harvested on day 14
demonstrate that all five tumors derived from tumors overex-
pressing GLUT1 are larger (by 6–73%) than the contralateral
tumor (data not shown).
Immunoblot and immunohistochemistry analysis demonstrated
that tumors derived from 85815GL cells overexpressing GLUT1
maintain robust expression of GLUT1 while the control tumors
have very little GLUT1 expression (Figure 7C–D). Low power
photomicrographs of cleaved caspase 3 stained sections demon-
strate that tumors derived from 85815GL cells overexpressing
GLUT1 appear to have less apoptosis than the control tumors
(Figure 7E left), which is in contrast to the low levels of cleaved
caspase 3 observed in the previous two models (Figures 3E and
5E). Indeed, tumors overexpressing GLUT1 have five times less
cleaved caspase 3 staining than the control tumors (Figure 7F).
Tumors derived from 85815GL cells overexpressing GLUT1 also
have increased proliferation as determined by BrdU nuclear
incorporation (Figure 7G–H). These data suggest that the
increased tumor formation by 85815GL cells overexpressing
GLUT1 results from both a decrease in apoptosis and an increase
in proliferation.
Discussion
We have demonstrated that GLUT1 is the most highly
expressed hexose transporter in ErbB2- and PyVMT-induced
mouse mammary carcinoma models, and that reducing the level of
GLUT1 using shRNA or Cre/lox results in reduced glucose usage,
reduced growth on plastic and in soft agar, and impaired tumor
growth in nude mice. Cells with low levels of GLUT1 demonstrate
reduced flux of glucose into lipid, while the ATP concentrations
appear unaffected by impaired GLUT1 expression suggesting that
reduced glucose consumption impairs lipid synthesis rather than
ATP production. Overexpression of GLUT1 in a cell line that has
very low levels of GLUT1 increases glucose transport and
increases tumor growth (while cell proliferation is unaffected by
GLUT1 overexpression in vitro). Together, this suggests that
GLUT1 and glucose usage are important aspects in the tumor cell
biology of breast cancer cells and impact both tumor growth and
survival. This has also been suggested by groups who inhibited
GLUT1 in cancer cells derived from other tissues, although most
of this work focused on cell culture models [17,36,37].
Expression of GLUT1 is regulated by a number of mechanisms.
Hypoxia induces the stabilization of the HIF transcription factors
which induce expression of GLUT1 along with a panel of
glycolysis genes [3]. In our study, we harvested our tumors when
they were relatively small (,200 mg), in an attempt to address
GLUT1 function in tumors with minimal or no hypoxia. A
number of cancer genes, including Myc [38], Akt [7], Ras [6,39],
Raf [39], Src [6,40], EGFR [10], and loss of p53 [41,42] induce
increased glucose uptake which is associated with an increase in
glycolysis. Some of these genes are known to promote localization
of GLUT1 at plasma membrane [43,44] or induce transcription of
the GLUT1 gene [6,39,45,46]. These diverse mechanisms by
which cancer cells induce GLUT1 suggest that GLUT1 could be a
Figure 7. Overexpression of GLUT1 in 85815GL cells acceler-
ates tumor formation. A. 0.4 million 85815GL cells expressing
control vector (V) or GLUT1 (G1) were injected into contralateral #4
mammary fat pads of athymic nude mice. Bioluminescence from the
labeled tumor cells was detected on days 3, 6, 9, 12 and 14 after
implantation. B. The bioluminescence on days 3, 6, 9, 12 and 14
normalized to the day 3 value was averaged for all five mice and is
presented +/2SEM. C. GLUT1 and b-actin expression evaluated in
lysates of three tumor pairs by immunoblot analysis. D. GLUT1
expression evaluated by IHC in two tumor pairs. E. Low power
photomicrographs of a pair of tumor sections derived from a vector
control tumor (top) and a tumor overexpressing GLUT1 (bottom)
immunostained for cleaved caspase 3 (left). High power photomicro-
graphs of a pair of tumor sections immunostained for cleaved caspase 3
(middle), which are converted to binary pictures (right). F. Quantifica-
tion of the number of cleaved caspase 3 positive pixels in five high
power field ‘‘hot spots’’ in four tumors of each group. G–H.
Representative high power photomicrographs of tumor sections
immunostained for BrdU with hematoxylin counterstain (G) which is
quantified (H).
doi:10.1371/journal.pone.0023205.g007
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clinical investigation. Our data suggests that targeting GLUT1
alone may not suffice to kill tumor cells, but it may prove as a
useful target in combination with therapies that target other
molecules that regulate tumor metabolism. For example, inhibi-
tion of GLUT1 in combination with chemotherapeutic drugs
cooperatively induced growth arrest and killed cancer cells in
another model [37]. Therapies that when combined with targeted
blockade of GLUT1 produce the best therapeutic index may be
readily predicted based upon our current understanding of tumor
metabolism since it is clear that tumors readily adapt to metabolic
challenges. Thus unbiased approaches will be required to identify
the best approaches to attack the altered metabolism present in
tumors cells. It is also important to note that while the inhibition of
glucose usage, lactate secretion and lipid synthesis appears to be
modest in cells with reduced GLUT1 expression, these affects are
similar to what has been observed in cells with inhibited PI3K/
mTOR signaling by genetic or pharmacologic means [47,48].
Two recent studies demonstrate interesting relationships
between cancer oncogenes (KRAS, BRAF and ErbB2), regulation
of glucose transport and cell survival under conditions of stress
[39,49]. Cancer cells with mutant KRAS or BRAF have higher
levels of GLUT1 RNA and protein expression and higher rates of
glucose uptake and glycolysis which allows the cells to survive in
conditions of low glucose [39]. Cancer cells with wild type KRAS
survived poorly in conditions of low glucose, but those that did
survive upregulated GLUT1 and a small percentage acquired
mutations in KRAS [39]. This data is compelling because it
suggests that GLUT1 is an important stress-responsive mediator of
cancer cell survival when glucose is limiting, making it an
attractive therapeutic target. However, it also suggests that
conditions of low glucose, which may be mimicked by reducing
GLUT1 levels or function, may in fact select for mutations which
would potentially lead to a more aggressive tumor. The second
study demonstrated that mammary epithelial cells suffer a
reduction in glucose transport and ATP production when they
are detached from the substratum, but these deficiencies can be
rescued by expression of ErbB2 [49]. This study links cell
detachment, a condition necessary for migration/invasion, with
sustained glucose transport and ErbB2 overexpression. This may
be an important aspect to consider since the cells utilized in our
study overexpress ErbB2 and maintained ATP levels when
GLUT1 expression was reduced.
An alternative glycolytic pathway utilizing the M2 isoform of
pyruvate kinase [50,51] and identification of SGLT1 in EGFR
expressing cancer cells [10] are recent discoveries in the field of
cancer cell glucose metabolism which deviate from the dogmatic,
textbook representation of glycolysis and suggest there is much still
to learn about cancer cell metabolism. The use of the M2 isoform
of pyruvate kinase by cancer cells is actually enzymatically
inefficient, but promotes anabolic processes necessary for cancer
cell growth and may in fact uncouple glycolysis from ATP
production [51]. We observed decreased lipid synthesis in cells
with reduced GLUT1 expression while ATP concentrations were
unaltered, which suggests that this anabolic processes is affected by
limiting GLUT1. Data demonstrating expression of the SGLT1
glucose transporter in tumor cells expressing EGFR [10] suggests
that this second family glucose transporters merits examination in
addition to the GLUT family. We were unable to detect SGLT1
RNA or protein expression in our systems, despite the fact that the
EGFR was expressed in the mammary carcinoma cell lines.
Glutamine and fatty acid metabolism are also critical for tumor
cell proliferation [52,53,54,55] and both of these carbon sources
may replace or supplement the need for glucose; therefore these
pathways must also be analyzed to gain a full picture of tumor cell
metabolism. The metabolism of cancer cells is likely to be quite
complex and appears to be quite adaptable in terms of carbon
sources that can be utilized. The work presented here represents a
single aspect of what is needed to fully understand cancer cell
metabolism and how this understanding may impact the
management or prognosis of affected patients.
Supporting Information
Figure S1 Colonies of 78617GL cells expressing control
shRNA (shCTRL) or GLUT1 shRNA (shGLUT1) were
grown in soft agar for three weeks (pictured in A) before
being incubated 1 hr with 3 mg/ml BrdU then fixed in
10% neutral buffered formalin, embedded in paraffin,
sectioned and stained by IHC for cleaved caspase 3 (B)
or BrdU (C).
(TIF)
Figure S2 Schematic representation of the murine
GLUT1 allele, the targeting vector and the recombinant
allele. 59 and 39 probes that were used for Southern blot
verification of homologous integration of the GLUT1
allele, and location of PCR primers that were used to
additional verify 59 integration is shown.
(TIF)
Figure S3 Schematic representation of wildtype, loxP-
frt-Neo-frt-loxP, floxed GLUT1 allele, and deleted
GLUT1 allele after Cre-mediated recombination are
illustrated, along with a representative PCR analysis of
the WT and loxP-frt-Neo-frt-loxP allele. Location of primers
used for genotyping are illustrated. PCR Primer sequences are:
2.85F – ctgtgagttcctgagaccctg; 2.9R – cccaggcaaggaagtagttc;
FRTF – ctccattctccaaactaggaac; FRT-R2 – gaaggcacatatgaaa-
caatg.
(TIF)
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